Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials

Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrut...

Full description

Saved in:
Bibliographic Details
Published inJournal of Immunotherapy and Precision Oncology Vol. 5; no. 2; pp. 43 - 47
Main Authors Htut, Thura Win, Han, Myat Min, Thein, Kyaw Zin
Format Journal Article
LanguageEnglish
Published United States Innovative Healthcare Institute 01.05.2022
Subjects
acalabrutinib
atrial fibrillation
cardiac toxicities
chronic lymphocytic leukemia
hypertension
Review
atrial fibrillation
chronic lymphocytic leukemia
hypertension
cardiac toxicities
acalabrutinib
Online AccessGet full text

Cover

More Information
Summary:Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2666-2345
2590-017X
DOI:10.36401/JIPO-21-12